Platin‐based exclusive chemotherapy for selected patients with squamous cell carcinoma of the larynx and pharynx

Abstract

For selected patients, EC may provide long-term, durable disease control. For patients who developed recurrent disease after EC, this approach did not diminish survival and maintained function in the majority of patients. Future work should be directed toward select markers of response to PF chemotherapy with which to identify those patients who are suited optimally for this approach.